|
|
|
VGX Pharmaceuticals
Strengthens Management Team with Two New Appointments:
Dorothy Peterson Appointed as Director of Quality
Debra A. Bacino Appointed as Controller
|
| Blue
Bell, PA – May 2, 2007 – |
|
VGX Pharmaceuticals announced the appointment of two
senior biotechnology industry professionals to strengthen the company’s
manufacturing operations and finance. Dorothy Peterson will serve as Director
of Quality and Debra A. Bacino, CPA will serve as Controller for VGX Pharmaceuticals.
Ms. Peterson comes to VGX with over 20 years experience in the medical
device industry complying with FDA regulations in both start up and established
organizations. Ms. Peterson recently relocated to Houston, TX from San
Diego, CA where she was VP of Operations at Qualigen, Inc. which included
the responsibility for quality and regulatory affairs. While at Qualigen,
she successfully submitted several 510(k) applications and led the company
through multiple regulatory agency audits including ISO 13485 to gain
the CE mark. Prior to Qualigen, Ms. Peterson was at Hybritech, Inc. (a
subsidiary of Beckman-Coulter) where she held multiple positions in both
the quality and manufacturing organizations. Ms. Peterson received her
Bachelor of Science in Biology from Sam Houston State University in Huntsville,
Texas. She is also a member of the Regulatory Affairs Professional Society.
Ms. Bacino has over 25 years of financial experience focused in both major
pharmaceutical companies as well as biotechnology. She served as Controller
for Eximias Pharmaceutical Corporation, a development stage biotechnology
company, where she was responsible for building and managing the corporate
financial and human resource infrastructure. Prior to Eximias, Ms. Bacino
was Plant Controller for a Novartis Consumer Health production facility.
Before Novartis, she maintained a successful career with Rhône-Poulenc
Rorer in increasingly responsible positions in divisional finance, corporate
finance, financial budgeting, planning and analysis, auditing and general
accounting. Ms. Bacino received her Bachelor of Arts degree in Mathematics
from West Chester University. She is a Certified Public Accountant licensed
in the state of Pennsylvania.
Dr. J. Joseph Kim, President and CEO of VGX commented, “We are very
pleased to have Dorothy and Debra join VGX as we look to expand and grow
our business operations by recruiting key professionals. Dorothy brings
a wealth of operational, quality and regulatory experience and further
strengthens our ability to provide our clients with world-class cGMP manufacturing
services. Debra strengthens our financial operations by bringing in broad
accounting and corporate finance experience as we get closer to our overall
goal of becoming a publicly traded global biopharmaceuticals company.”
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About VGX
Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company with small molecules
and biologics product candidates for the treatment of infectious diseases,
cancer and inflammatory diseases. The Company’s clinical development
programs include PICTOVIR™ for HIV infection and VGX-410C for chronic
HCV infection, both of which are currently in Phase II clinical trials.
In addition, Phase I clinical trials will be initiated in 2007 for VGX-150
for the treatment of Melanoma and VGX-1027 for inflammatory diseases. VGX’s
research pipelines include new generation of DNA vaccines and therapeutics
as well as CELLECTRA™, a proprietary DNA delivery device. The product
candidates and technology programs are protected by the Company’s
extensive global intellectual property portfolio. More information about
VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
